enVVeno Medical (NVNO) Depreciation & Amortization (CF) (2017 - 2026)

enVVeno Medical's Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $31000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 22.5% year-over-year to $31000.0 in Q1 2026; TTM through Mar 2026 was $127000.0, a 27.01% decrease from a year earlier, with the FY2025 full-year figure at $136000.0, down 28.04% from the prior year.
• Depreciation & Amortization (CF) held at $31000.0 in Q1 2026 per NVNO's latest filing, from $31000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $56000.0 in Q3 2023 and bottomed at $31000.0 in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $51000.0 (2022), against an average of $46352.9.
• Across the five-year window, Depreciation & Amortization (CF) surged 82.14% in 2022 and sank 33.33% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $54000.0 in 2022, then climbed by 1.85% to $55000.0 in 2023, then slipped by 27.27% to $40000.0 in 2024, then fell by 22.5% to $31000.0 in 2025, then changed by 0.0% to $31000.0 in 2026.
• Per Business Quant, the three latest NVNO Depreciation & Amortization (CF) figures stand at $31000.0 (Q1 2026), $31000.0 (Q4 2025), and $31000.0 (Q3 2025).